Analyst Views Diverge as Alnylam Pharmaceuticals, Inc. (ALNY) Targets $5.1B Revenue and Long-Term Growth

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the best healthcare stocks to buy for 2026. On January 20, RBC Capital reiterated an Outperform rating on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) but cut the price target to $465 from $500. Analyst Views Diverge as Alnylam Pharmaceuticals, Inc. (ALNY) Targets $5.1B Revenue and Long-Term Growth The new price outlook comes on Alnylam Pharmaceuticals announcing strategic priorities for the year, including achieving revenue of $5.1 billion, exceeding ...